アラバマ州における肺がんの臨床試験
アラバマ州内の拠点で、肺がんに関する16件の研究が参加者を募集しています。
アラバマ州内の都市
公式研究テキスト（英語）
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Alabama Oncology, Birmingham
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT06881784Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
- Clearview Cancer Institute (Crestwood), Huntsville
- Clearview Cancer Institute, Huntsville
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07489066A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- University of Alabama at Birmingham, Birmingham
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07154290A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- University of Alabama at Birmingham, Birmingham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT06618287Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- Birmingham Hematology and Oncology Associates LLC d/b/a Alabama Oncology, Birmingham
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06712316Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Alabama Birmingham, Birmingham
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/10更新 · NCT06293898A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Clearview Cancer Institute, Huntsville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06119581Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
- O'Neal Comprehensive Cancer Center at UAB, Birmingham
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06343402Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- University of Alabama at Birmingham Cancer Center, Birmingham
- The Kirklin Clinic at Acton Road, Birmingham
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis, Daphne
- 他3件
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05624996Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis, Daphne
- Thomas Hospital, Fairhope
- Mobile Infirmary Medical Center, Mobile
- 他1件
被験者募集中第2相
18歳以上 · 全性別 · 2026/06/03更新 · NCT05642572MYLUNG Consortium Part 3: Observational Study
- Southern Cancer Center, PC, Daphne
被験者募集中観察研究
18歳以上 · 全性別 · 2026/05/18更新 · NCT05885698Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis, Daphne
- Thomas Hospital, Fairhope
- Mobile Infirmary Medical Center, Mobile
- 他1件
被験者募集中第2相
18 Minutes · 全性別 · 2026/05/05更新 · NCT06031688Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis, Daphne
- Thomas Hospital, Fairhope
- Mobile Infirmary Medical Center, Mobile
- 他1件
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/05/05更新 · NCT06616584Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- University of Alabama at Birmingham, Birmingham
- University of South Alabama, Mobile
被験者募集中
18歳以上 · 全性別 · 2026/04/30更新 · NCT05297734SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Birmingham
- Massive Bio SYNERGY-AI site, Mobile
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
- XCancer Research Network/Dothan Hematology & Oncology, Dothan
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/10/24更新 · NCT06228326ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。